Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

convEyXO and SomesTech Announce XomeXBio Joint Venture to Unleash Full Potential of Targeted Exosomes as drug delivery system for precision medicine

May 28, 2023 By Cade Hildreth, Founder & President Leave a Comment

The collaboration includes the development, commercialization and supply of a breakthrough platform based on SomesTech nanoengineering technology strengthened and validated by convEyXO to enable loading of exosomes capable to delivering bioactive compounds in a targeted way.

[Read more…]

Ronawk Announces the Launch of STELLα: A Groundbreaking Non-Clinical Contract Research Organization (CRO)

May 25, 2023 By Cade Hildreth, Founder & President Leave a Comment

Overland Park, KS – Ronawk, a leading biotechnology company, proudly announces the launch of STELLα, a state-of-the-art non-clinical contract research organization (CRO) dedicated to driving innovation in the life sciences industry. The addition of STELLα to Ronawk’s portfolio represents a significant milestone in the company’s growth and expansion, further solidifying its position as a strategic contributor to the region’s growing biotech ecosystem. [Read more…]

FDA-Approved Phase II Stem Cell Trial Shows Significant Improvements for Multiple Sclerosis (MS) Patients

May 7, 2023 By Cade Hildreth, Founder & President 2 Comments

The findings of this study suggest that stem cells could have major implications for treating MS and reversing patient disability even after significant progression.

The study, from the Tisch MS Research Center of New York, is the first to link stem cells with a broad array of improvements. Progressive MS patients demonstrated better outcomes in walking speeds, gray matter volume, bladder function, and biomarker indicators.

[Read more…]

Oncofocus, a management consulting firm, is offering the live demonstration of Novus AI, its conference intelligence platform

May 5, 2023 By Cade Hildreth, Founder & President Leave a Comment

BENGALURU, KARNATAKA, INDIA, MAY 04, 2023 – Oncofocus Solutions, a management consulting firm established in 2014 to cater to the business intelligence needs in the Oncology domain, is offering the live demo of Novus AI, its cutting-edge AI-powered conference intelligence platform. [Read more…]

Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis

May 4, 2023 By Cade Hildreth, Founder & President Leave a Comment

First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS).

CK0803 is derived from clinical-grade umbilical cord blood units

Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803.

HOUSTON, May 2, 2023 — Cellenkos^® Inc., a clinical stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory cell therapies for treatment of rare inflammatory diseases and autoimmune disorders, announced that it has dosed the first patient in a Phase 1/1b study evaluating CK0803 for treatment of amyotrophic lateral sclerosis (ALS) (under National Clinical Trial registry NCT05695521). [Read more…]